Cargando…

Investigating imaging network markers of cognitive dysfunction and pharmacoresistance in newly diagnosed epilepsy: a protocol for an observational cohort study in the UK

INTRODUCTION: Epilepsy is one of the most common serious brain disorders, characterised by seizures that severely affect a person’s quality of life and, frequently, their cognitive and mental health. Although most existing work has examined chronic epilepsy, newly diagnosed patients present a unique...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bézenac, Christophe, Garcia-Finana, Marta, Baker, Gus, Moore, Perry, Leek, Nicola, Mohanraj, Rajiv, Bonilha, Leonardo, Richardson, Mark, Marson, Anthony Guy, Keller, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797398/ https://www.ncbi.nlm.nih.gov/pubmed/31619436 http://dx.doi.org/10.1136/bmjopen-2019-034347

Ejemplares similares

Altered structural connectome in non-lesional newly diagnosed focal epilepsy: Relation to pharmacoresistance
por: Kreilkamp, Barbara A.K., et al.
Publicado: (2021)

Cortical stimulation in pharmacoresistant focal epilepsies
por: Ellrich, Jens
Publicado: (2020)

Genetic variations associated with pharmacoresistant epilepsy
por: Cárdenas-Rodríguez, Noemí, et al.
Publicado: (2020)

NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy
por: Warburton, Alix, et al.
Publicado: (2016)

Vagal nerve stimulation for pharmacoresistant epilepsy in children
por: Hauptman, Jason S., et al.
Publicado: (2012)

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2022)

Pharmacoresistant Abdominal Seizures in Symptomatic Localization-Related Epilepsy
por: Tushar, Vadakke Puthanveetil, et al.
Publicado: (2021)

The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies
por: Fattorusso, Antonella, et al.
Publicado: (2021)

Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?
por: Czornyj, Liliana, et al.
Publicado: (2021)

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2023)

Fiber ball white matter modeling in focal epilepsy
por: Bryant, Lorna, et al.
Publicado: (2021)

Effect of Oxidative Stress on ABC Transporters: Contribution to Epilepsy Pharmacoresistance
por: Grewal, Gurpreet Kaur, et al.
Publicado: (2017)

A complex systems view on the current hypotheses of epilepsy pharmacoresistance
por: Servilha‐Menezes, Gabriel, et al.
Publicado: (2022)

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
por: Marson, Anthony, et al.
Publicado: (2021)

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial
por: Marson, Anthony, et al.
Publicado: (2021)

Lower fat and better quality diet therapy for children with pharmacoresistant epilepsy
por: Yoon, Jung-Rim, et al.
Publicado: (2013)

7T MRI with post-processing for the presurgical evaluation of pharmacoresistant focal epilepsy
por: Chen, Cong, et al.
Publicado: (2021)

‘Hippocampal innate inflammatory gliosis only’ in pharmacoresistant temporal lobe epilepsy
por: Grote, Alexander, et al.
Publicado: (2022)

Limbic network co‐localization predicts pharmacoresistance in dysplasia‐related epilepsy
por: Cohen, Nathan T., et al.
Publicado: (2023)

Effects of Surgical Side and Site on Mood and Behavior Outcome in Children with Pharmacoresistant Epilepsy
por: Andresen, Elizabeth N., et al.
Publicado: (2014)

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program
por: Contin, Manuela, et al.
Publicado: (2021)

Pharmacoresistant Epilepsy in Childhood: Think of the Cerebral Folate Deficiency, a Treatable Disease
por: Mafi, Sarah, et al.
Publicado: (2020)

Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy
por: El-Tallawy, Hamdy N, et al.
Publicado: (2021)

Network Substrates of Centromedian Nucleus Deep Brain Stimulation in Generalized Pharmacoresistant Epilepsy
por: Torres Diaz, Cristina V., et al.
Publicado: (2021)

Multi‐omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy
por: Bruxel, Estela M., et al.
Publicado: (2021)

Pharmacoresistant Epilepsy: A Current Update on Non-Conventional Pharmacological and Non-Pharmacological Interventions
por: Sharma, Arun Kumar, et al.
Publicado: (2015)

Bilateral stereotactic lesions and chronic stimulation of the anterior thalamic nuclei for treatment of pharmacoresistant epilepsy
por: Sitnikov, A. R., et al.
Publicado: (2018)

A Clinical-EEG Study of Sleepiness and Psychological Symptoms in Pharmacoresistant Epilepsy Patients Treated with Lacosamide
por: Giorgi, Filippo S., et al.
Publicado: (2013)

Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities
por: Chen, Fan, et al.
Publicado: (2019)

Radiological and Clinical Value of 7T MRI for Evaluating 3T-Visible Lesions in Pharmacoresistant Focal Epilepsies
por: Wang, Z. Irene, et al.
Publicado: (2021)

Reduction in anti-seizure medications use in pediatric patients with pharmacoresistant epilepsy submitted to surgical treatment
por: de Matos, Maiave Micaelle Figueiredo, et al.
Publicado: (2022)

Vagus nerve stimulation for pharmacoresistant epilepsy secondary to encephalomalacia: A single-center retrospective study
por: Guo, Mengyi, et al.
Publicado: (2023)

Brain functional connectivity‐based prediction of vagus nerve stimulation efficacy in pediatric pharmacoresistant epilepsy
por: Chen, Hao, et al.
Publicado: (2023)

FALSE PHARMACORESISTANCE – A TRUE PROBLEM
por: Bašić, Silvio, et al.
Publicado: (2021)

Association of Epilepsy Surgery With Changes in Imaging-Defined Brain Age
por: de Bézenac, Christophe E., et al.
Publicado: (2021)

Endocannabinoid System and Cannabinoid 1 Receptors in Patients With Pharmacoresistant Temporal Lobe Epilepsy and Comorbid Mood Disorders
por: Rocha, Luisa, et al.
Publicado: (2020)

Chaotic and stochastic dynamics of epileptiform-like activities in sclerotic hippocampus resected from patients with pharmacoresistant epilepsy
por: Araújo, Noemi S., et al.
Publicado: (2022)

DELAYED EFFECT OF VNS ON INTERICTAL EPILEPTIFORM DISCHARGES AND PHARMACORESISTANCE IN A PATIENT WITH REFRACTORY PERINATAL POSTISCHEMIC EPILEPSY
por: Sporiš, Davor, et al.
Publicado: (2021)

Spectrum of Electroencephalography Findings in Newly Diagnosed Epilepsy
por: Khalily, Muhammad A, et al.
Publicado: (2021)

Probabilistic mapping of thalamic nuclei and thalamocortical functional connectivity in idiopathic generalised epilepsy
por: Chen, Yachin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s2su4poovdbl0ml26pkf634gm6